Compare Cardinal Health Inc (CAH) vs DuPont de Nemours Inc (DD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs DuPont de Nemours Inc — how do they compare? Cardinal Health Inc trades at $241.5 (market cap $55.55B), while DuPont de Nemours Inc trades at $144.26 (market cap $19.12B). The key difference: Cardinal Health Inc is far larger — about 2.9× DuPont de Nemours Inc's market cap, and DuPont de Nemours Inc pays the higher dividend (1.7%). Which is the better fit depends on your goals.
| CAH | DD | |
|---|---|---|
Market Cap | $55.55B | $19.12B |
Sector | Health | Basic Materials |
52-Week High | $239.71 | $154.59 |
52-Week Low | $146.04 | $87.72 |
Enterprise Value | $60.53B | $20.50B |
Dividend Yield | 0.86% | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $236.4, down 0.53% on the day, with a bullish technical outlook and strong earnings momentum after beating estimates for three consecutive quarters. The company reported $222.58B in revenue for 2025, with net income rising to $1.56B, and recently announced two home-care acquisitions to expand its at-Home Solutions segment. Analyst sentiment is positive, with a consensus price target of $262.80 and no sell ratings among 33 analysts.
The stock presents a favorable risk-reward profile with upside to the consensus target, supported by earnings beats and strategic growth initiatives. Key risks include high leverage with a debt-to-asset ratio of 16.09 in 2025 and thin net margins of 0.62%, which could pressure profitability if revenue growth slows or interest costs rise.
DuPont (DD) trades at $142.48, down 1.06% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported Q2 2026 earnings that beat expectations, with EPS of $1.88 versus $1.76 expected, and raised its full-year 2026 outlook, driven by healthcare, industrial water, and aerospace demand. However, 2025 fundamentals show a net loss of $779 million on revenue of $6.85 billion, with a high P/E ratio of 61.15 indicating premium valuation.
The outlook is cautiously optimistic, supported by earnings momentum and innovation awards, but risks include ongoing legal settlements over PFAS chemicals and thin net margins. The consensus price target of $232.80 suggests significant upside potential if operational improvements continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →
